Vericel Corp (NASDAQ:VCEL) shares saw unusually-strong trading volume on Monday . Approximately 710,426 shares traded hands during trading, an increase of 29% from the previous session’s volume of 550,490 shares.The stock last traded at $18.94 and had previously closed at $18.66.

A number of research analysts have recently commented on VCEL shares. Needham & Company LLC reissued a “hold” rating on shares of Vericel in a report on Tuesday, November 5th. HC Wainwright started coverage on Vericel in a report on Wednesday, October 9th. They issued a “buy” rating and a $19.00 target price on the stock. BidaskClub raised Vericel from a “hold” rating to a “buy” rating in a report on Tuesday, October 29th. Zacks Investment Research reaffirmed a “buy” rating and issued a $16.00 target price on shares of Vericel in a report on Saturday, October 12th. Finally, BTIG Research set a $24.00 target price on Vericel and gave the company a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.78.

The company has a market cap of $851.79 million, a price-to-earnings ratio of -135.29 and a beta of 2.72. The company has a fifty day moving average price of $17.30 and a two-hundred day moving average price of $17.03. The company has a current ratio of 6.93, a quick ratio of 6.48 and a debt-to-equity ratio of 0.26.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.09. The company had revenue of $30.50 million for the quarter, compared to analyst estimates of $26.84 million. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. Vericel’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.02) EPS. Sell-side analysts anticipate that Vericel Corp will post 0.16 EPS for the current fiscal year.

In related news, CEO Dominick Colangelo sold 58,125 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total transaction of $864,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Halpin sold 15,047 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $18.53, for a total value of $278,820.91. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in shares of Vericel by 665.8% during the 2nd quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,345 shares during the period. Advisor Group Inc. raised its position in Vericel by 152.1% in the 2nd quarter. Advisor Group Inc. now owns 2,652 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 1,600 shares during the last quarter. Advisory Services Network LLC raised its position in Vericel by 100.0% in the 2nd quarter. Advisory Services Network LLC now owns 3,000 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,500 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in Vericel in the 3rd quarter valued at $61,000. Finally, Aperio Group LLC bought a new position in Vericel in the 2nd quarter valued at $67,000. Institutional investors and hedge funds own 86.86% of the company’s stock.

Vericel Company Profile (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Read More: How is an ETF different from a mutual fund?

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.